SCHEMBL24728131

SCHEMBL24728131

COc1ccc(N)c(-c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 2/20 0.48
MAOB P27338 1/20 0.48
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
SYK P43405 1/20 0.46
ABCB1 P08183 3/20 0.45
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7689083 0.84 MAPT (0.59) C5AR1MAOBMAPTMAPK1ALDH1A1
SCHEMBL3915606 0.81 MAOB (0.58) MAOBABCB1HTR1ADRD2MAPT
SCHEMBL30189780 0.81 MAOB (0.58) MAOBABCB1HTR1ADRD2MAPT
SCHEMBL9315251 0.81 MAOB (0.58) MAOBABCB1HTR1ADRD2MAPT
SCHEMBL18487331 0.80 C5AR1 (0.47) C5AR1MAOBCTSLCTSBABCB1
SCHEMBL1026336 0.79 MAOB (0.54) C5AR1MAOBABCB1HTR1ADRD2
SCHEMBL12772071 0.77 MAOB (0.62) MAOBABCB1HTR1ADRD2KDM4E
SCHEMBL13791570 0.77 MAOB (0.62) MAOBABCB1HTR1ADRD2MAPT
SCHEMBL3781528 0.76 APP (0.47) MAOBMAPTMAPK1KDM4EALDH1A1
SCHEMBL3793161 0.76 GSTP1 (0.57) MAOBMAPTMAPK1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473264-B2 Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof PURDUE RESEARCH FOUNDATION (US) 2025-11-18 US disclosed
US-20220388968-A1 INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF PURDUE RESEARCH FOUNDATION 2022-12-08 US disclosed
US-20220388968-A1 INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF PURDUE RESEARCH FOUNDATION 2022-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388968-A1 INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF SPTBN1, CTTN, HBG1 C5AR1 4080/4885MAOB 3013/4885CTSL 3933/4885
US-12473264-B2 Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof HBG1, SPTBN1, CTTN C5AR1 2818/4885MAOB 2588/4885CTSL 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.